5 November 2015 - The U.S. FDA today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471300.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery